[Ip-health] blogpost on Gilead's earnings and HCV treatment access problems and opportunities at the VA

Steven Knievel sknievel at citizen.org
Tue Aug 4 14:08:38 PDT 2015

Hello all -

I put together a short post on the heels of Gilead's announcement of Q2 2015 earnings about the company's astronomical profits from its HCV drugs as well as recent developments regarding access to treatment at the Department of Veterans Affairs (VA). 


Here's a snip:

At the VA, the combination of the high prices of these products and a limited budget has led to restrictions in access. The VA spent $379 million on new hepatitis C treatments in FY2014. Thus far in 2015, they've spent $700 million, which was intended to last through the entire fiscal year but was completely exhausted as of June.


At its peak, the VA was newly enrolling ~800 patients per week on HCV treatment. By June 10, that number was down to less than 300. Before the end of the month it fell to zero.


Please feel free to drop me a line with any questions or comments.



Steven Knievel
Campaign Coordinator | Global Access to Medicines Program
Public Citizen | Protecting Health, Safety and Democracy
TEL: +1 202-588-7769
1600 20th St. NW, Washington, DC 20009
URL: http://www.citizen.org/access  
Twitter: @PCMedsAccess

Public Citizen Foundation participates in the Combined Federal Campaign with the CFC Code 11168.

More information about the Ip-health mailing list